Literature DB >> 28412824

Assessment of Lean Patients with Non-alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association with Metabolic Disorders: A Cross-sectional Study.

Mohammadreza Naderian1, Shadi Kolahdoozan2, Amir Sina Sharifi2, Gholamreza Garmaroudi3, Mehdi Yaseri4, Hossein Poustchi2, Amir Ali Sohrabpour2.   

Abstract

BACKGROUND: Recent data has proven that the WHO (world health organization) cut-off for obesity is not applicable to the Asian population. This study aims to estimate the prevalence of lean NAFLD (non-alcoholic fatty liver disease) in the capital of Iran and extract probable predictors for this growing health issue in this population.
METHODS: This is a population-based cross-sectional study on apparently healthy subjects over 18 years of age. The participants were interviewed for baseline demographic and clinical information. They were subsequently referred for physical examination and blood sampling. NAFLD was diagnosed using abdominal ultrasonography by a single expert radiologist.
RESULTS: Of 927 eligible participants who entered the study, 314 were lean; BMI (body mass index) <25 kg/m2. The prevalence of NAFLD was 17.52% (95% Exact CI: 13.48%-22.18%). BMI, SBP (systolic blood pressure), DBP (diastolic blood pressure), total cholesterol, HDL (high-density lipoprotein), LDL (low-density lipoprotein) and triglyceride were significantly different in patients with NAFLD. In the final multiple analysis, higher levels of triglyceride, upper SBP and higher BMI even in the range of less than 25 kg/m2 were independent predictors of NAFLD in lean participants. In lean participants with more components of metabolic syndrome, the prevalence of NAFLD increased significantly (all P < 0.01). BMI cut-offs in men and women along with waist circumference cut-off in men could significantly predict the presence of NAFLD in lean patients. After comparing these values, McNemar test showed that BMI cut-offs are more robust than waist circumference cut-offs for predicting the presence of NAFLD in lean subjects (P < 0.01).
CONCLUSION: The prevalence of NAFLD in lean subjects in a sample of Iranian population is 17.52%. Hypertriglyceridemia, higher SBP, and higher BMI especially over 23.2 are independent factors associated with the presence of NAFLD in lean subjects.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28412824     DOI: 0172004/AIM.005

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  5 in total

1.  Body mass index, waist circumference, and waist-to-height ratio for prediction of multiple metabolic risk factors in Chinese elderly population.

Authors:  Zhan Gu; Dong Li; Huayu He; Jianying Wang; Xiaojuan Hu; Peihua Zhang; Yanlong Hong; Baocheng Liu; Lei Zhang; Guang Ji
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

2.  Prevalence and Risk Factors of Elevated Liver Enzymes in Japanese Women With Polycystic Ovary Syndrome.

Authors:  Satomi Minato; Naoki Sakane; Kazuhiko Kotani; Shinsuke Nirengi; Ikuyo Hayashi; Akiko Suganuma; Ken Yamaguchi; Kenji Takakura; Narumi Nagai
Journal:  J Clin Med Res       Date:  2018-10-30

3.  Comparison of Clinical Characteristics Between Obese and Non-Obese Patients with Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Yifang Li; Yanzhen Chen; Xing Tian; Shanshan Zhang; Jian Jiao
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-06       Impact factor: 3.168

Review 4.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

5.  The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study.

Authors:  Ehimen C Aneni; Marcio Sommer Bittencourt; Catherine Teng; Miguel Cainzos-Achirica; Chukwuemeka U Osondu; Ahmed Soliman; Mouaz Al-Mallah; Matthew Buddoff; Edison R Parise; Raul D Santos; Khurram Nasir
Journal:  Am J Prev Cardiol       Date:  2020-10-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.